Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:730.

  • 2.

    Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008.

  • 3.

    Carbone PP, Kaplan HS, Musshoff K. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:18601861.

  • 4.

    Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:30593068.

    • Search Google Scholar
    • Export Citation
  • 5.

    Henry-Amar M, Friedman S, Hayat M. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991;114:361365.

    • Search Google Scholar
    • Export Citation
  • 6.

    Tubiana M, Henry-Amar M, Hayat M. Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease. Cancer 1984;54:885894.

    • Search Google Scholar
    • Export Citation
  • 7.

    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:15061514.

    • Search Google Scholar
    • Export Citation
  • 8.

    Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:12441244.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579586.

  • 10.

    Juweid ME, Stroobants S, Hoekstra OS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571578.

    • Search Google Scholar
    • Export Citation
  • 11.

    Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:18441854.

  • 12.

    Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma 2010;51:21712180.

    • Search Google Scholar
    • Export Citation
  • 13.

    Meignan M, Gallamini A, Itti E. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:18761881.

    • Search Google Scholar
    • Export Citation
  • 14.

    Barrington SF, Mikhaeel NG, Kostakoglu L. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:30483058.

    • Search Google Scholar
    • Export Citation
  • 15.

    Barrington SF, Qian W, Somer EJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:18241833.

    • Search Google Scholar
    • Export Citation
  • 16.

    Dann EJ. PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions. Curr Oncol Rep 2012;14:403410.

  • 17.

    Barrington SF, Kirkwood AA, Franceschetto A. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127:15311538.

    • Search Google Scholar
    • Export Citation
  • 18.

    Biggi A, Gallamini A, Chauvie S. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683690.

    • Search Google Scholar
    • Export Citation
  • 19.

    Gallamini A, Barrington SF, Biggi A. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:11071113.

    • Search Google Scholar
    • Export Citation
  • 20.

    Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012;120:49134920.

    • Search Google Scholar
    • Export Citation
  • 21.

    Radford J, Illidge T, Counsell N. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015;372:15981607.

    • Search Google Scholar
    • Export Citation
  • 22.

    Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:10661074.

    • Search Google Scholar
    • Export Citation
  • 23.

    de Wit M, Bohuslavizki KH, Buchert R. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001;12:2937.

    • Search Google Scholar
    • Export Citation
  • 24.

    Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:12251231.

    • Search Google Scholar
    • Export Citation
  • 25.

    Sher DJ, Mauch PM, Van Den Abbeele A. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:18481853.

    • Search Google Scholar
    • Export Citation
  • 26.

    Li J, Dabaja B, Reed V. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167174.

    • Search Google Scholar
    • Export Citation
  • 27.

    Hoppe BS, Flampouri S, Su Z. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449455.

    • Search Google Scholar
    • Export Citation
  • 28.

    Girinsky T, Pichenot C, Beaudre A. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218226.

    • Search Google Scholar
    • Export Citation
  • 29.

    Nieder C, Schill S, Kneschaurek P, Molls M. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:2020.

    • Search Google Scholar
    • Export Citation
  • 30.

    Paumier A, Ghalibafian M, Gilmore J. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2012;82:15221527.

    • Search Google Scholar
    • Export Citation
  • 31.

    Filippi AR, Ragona R, Fusella M. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 2013;3:216222.

    • Search Google Scholar
    • Export Citation
  • 32.

    Charpentier A-M, Conrad T, Sykes J. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose. Pract Radiat Oncol 2014;4:174180.

    • Search Google Scholar
    • Export Citation
  • 33.

    Filippi AR, Ciammella P, Piva C. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;89:370375.

    • Search Google Scholar
    • Export Citation
  • 34.

    Voong KR, McSpadden K, Pinnix CC. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiat Oncol 2014;9:9494.

    • Search Google Scholar
    • Export Citation
  • 35.

    Caraway NP. Strategies to diagnose lymphoproliferative disorders by fine-needle aspiration by using ancillary studies. Cancer 2005;105:432442.

    • Search Google Scholar
    • Export Citation
  • 36.

    Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004;22:30463052.

  • 37.

    Meda BA, Buss DH, Woodruff RD. Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol 2000;113:688699.

    • Search Google Scholar
    • Export Citation
  • 38.

    El-Galaly TC, d'Amore F, Mylam KJ. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:45084514.

    • Search Google Scholar
    • Export Citation
  • 39.

    Moulin-Romsee G, Hindie E, Cuenca X. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:10951105.

    • Search Google Scholar
    • Export Citation
  • 40.

    van der Kaaij MA, Heutte N, Meijnders P. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol 2012;30:291299.

    • Search Google Scholar
    • Export Citation
  • 41.

    Sieniawski M, Reineke T, Nogova L. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:7176.

    • Search Google Scholar
    • Export Citation
  • 42.

    van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168179.

    • Search Google Scholar
    • Export Citation
  • 43.

    Terenziani M, Piva L, Meazza C. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril 2009;91:935 e915–936.

    • Search Google Scholar
    • Export Citation
  • 44.

    Duhmke E, Franklin J, Pfreundschuh M. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:29052914.

    • Search Google Scholar
    • Export Citation
  • 45.

    Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol 2003;42:589604.

    • Search Google Scholar
    • Export Citation
  • 46.

    Bonadonna G, Bonfante V, Viviani S. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:28352841.

    • Search Google Scholar
    • Export Citation
  • 47.

    Bartlett NL, Rosenberg SA, Hoppe RT. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:10801088.

    • Search Google Scholar
    • Export Citation
  • 48.

    Koontz MZ, Horning SJ, Balise R. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013;31:592598.

    • Search Google Scholar
    • Export Citation
  • 49.

    Abuzetun JY, Loberiza F, Vose J. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol 2009;144:531537.

    • Search Google Scholar
    • Export Citation
  • 50.

    Engert A, Plutschow A, Eich HT. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640652.

  • 51.

    Advani RH, Hoppe RT, Baer D. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013;24:10441048.

    • Search Google Scholar
    • Export Citation
  • 52.

    Engert A, Schiller P, Josting A. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:36013608.

    • Search Google Scholar
    • Export Citation
  • 53.

    Raemaekers JM, Andre MP, Federico M. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:11881194.

    • Search Google Scholar
    • Export Citation
  • 54.

    Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol 2015;33:625633.

    • Search Google Scholar
    • Export Citation
  • 55.

    Sasse S, Klimm B, Gorgen H. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol 2012;23:29532959.

    • Search Google Scholar
    • Export Citation
  • 56.

    Noordijk EM, Thomas J, Ferme C. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) [abstract]. J Clin Oncol 2005;23(Suppl):Abstract 6505.

    • Search Google Scholar
    • Export Citation
  • 57.

    Eich HT, Diehl V, Gorgen H. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:41994206.

    • Search Google Scholar
    • Export Citation
  • 58.

    Horning SJ, Hoppe RT, Breslin S. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630637.

    • Search Google Scholar
    • Export Citation
  • 59.

    Chisesi T, Bellei M, Luminari S. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011;29:42274233.

    • Search Google Scholar
    • Export Citation
  • 60.

    Aversa SM, Salvagno L, Soraru M. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol 2004;112:141147.

    • Search Google Scholar
    • Export Citation
  • 61.

    Edwards-Bennett SM, Jacks LM, Moskowitz CH. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol 2010;21:574581.

    • Search Google Scholar
    • Export Citation
  • 62.

    Hoskin PJ, Lowry L, Horwich A. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27:53905396.

    • Search Google Scholar
    • Export Citation
  • 63.

    Advani RH, Hong F, Fisher RI. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol 2015;33:19361942.

    • Search Google Scholar
    • Export Citation
  • 64.

    Gordon LI, Hong F, Fisher RI. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684691.

    • Search Google Scholar
    • Export Citation
  • 65.

    von Tresckow B, Plutschow A, Fuchs M. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907913.

    • Search Google Scholar
    • Export Citation
  • 66.

    Johnson P, Federico M, Kirkwood A. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016;374:24192429.

    • Search Google Scholar
    • Export Citation
  • 67.

    Engert A, Haverkamp H, Kobe C. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:17911799.

    • Search Google Scholar
    • Export Citation
  • 68.

    Canellos GP, Anderson JR, Propert KJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:14781484.

    • Search Google Scholar
    • Export Citation
  • 69.

    Diehl V, Franklin J, Pfreundschuh M. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:23862395.

    • Search Google Scholar
    • Export Citation
  • 70.

    Engert A, Diehl V, Franklin J. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:45484554.

    • Search Google Scholar
    • Export Citation
  • 71.

    Borchmann P, Haverkamp H, Diehl V. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29:42344242.

    • Search Google Scholar
    • Export Citation
  • 72.

    Carde P, Karrasch M, Fortpied C. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol 2016;34:20282036.

    • Search Google Scholar
    • Export Citation
  • 73.

    Federico M, Luminari S, Iannitto E. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805811.

    • Search Google Scholar
    • Export Citation
  • 74.

    Mounier N, Brice P, Bologna S. ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/=4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:16221628.

    • Search Google Scholar
    • Export Citation
  • 75.

    Viviani S, Zinzani PL, Rambaldi A. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203212.

    • Search Google Scholar
    • Export Citation
  • 76.

    Merli F, Luminari S, Gobbi PG. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:11751181.

    • Search Google Scholar
    • Export Citation
  • 77.

    Fabian CJ, Mansfield CM, Dahlberg S. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994;120:903912.

    • Search Google Scholar
    • Export Citation
  • 78.

    Aleman BM, Raemaekers JM, Tomisic R. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2007;67:1930.

    • Search Google Scholar
    • Export Citation
  • 79.

    Johnson PWM, Sydes MR, Hancock BW. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010:33523359.

    • Search Google Scholar
    • Export Citation
  • 80.

    Laskar S, Gupta T, Vimal S. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:6268.

    • Search Google Scholar
    • Export Citation
  • 81.

    Kriz J, Reinartz G, Dietlein M. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2015;92:4653.

    • Search Google Scholar
    • Export Citation
  • 82.

    Carella AM, Bellei M, Brice P. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica 2009;94:146148.

    • Search Google Scholar
    • Export Citation
  • 83.

    Proctor SJ, Mackie M, Dawson A. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002;38:795806.

    • Search Google Scholar
    • Export Citation
  • 84.

    Duggan DB, Petroni GR, Johnson JL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607614.

    • Search Google Scholar
    • Export Citation
  • 85.

    Gallamini A, Rossi A, Patti C. Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses—second interim analysis of the GITIL/FIL HD0607 clinical trial [abstract]. Haematologica 2013;98(Suppl 2):Abstract P006.

    • Search Google Scholar
    • Export Citation
  • 86.

    Press OW, Li H, Schoder H. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:20202027.

    • Search Google Scholar
    • Export Citation
  • 87.

    Avigdor A, Bulvik S, Levi I. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010;21:126132.

    • Search Google Scholar
    • Export Citation
  • 88.

    Mauch P, Ng A, Aleman B. Report from the Rockefellar Foundation sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9–16, 2033, Bellagio, Italy. Eur J Haematol Suppl 2005:6876.

    • Search Google Scholar
    • Export Citation
  • 89.

    Franklin J, Pluetschow A, Paus M. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:17491760.

    • Search Google Scholar
    • Export Citation
  • 90.

    Ng A, Constine LS, Advani R. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer 2010;34:211227.

  • 91.

    Saslow D, Boetes C, Burke W. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:7589.

    • Search Google Scholar
    • Export Citation
  • 92.

    Heidenreich PA, Hancock SL, Lee BK. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743749.

  • 93.

    Adams MJ, Lipsitz SR, Colan SD. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:31393148.

    • Search Google Scholar
    • Export Citation
  • 94.

    Aleman BM, van den Belt-Dusebout AW, De Bruin ML. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:18781886.

  • 95.

    Girinsky T, M'Kacher R, Lessard N. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. Int J Radiat Oncol Biol Phys 2014;89:5966.

    • Search Google Scholar
    • Export Citation
  • 96.

    Behringer K, Breuer K, Reineke T. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:75557564.

    • Search Google Scholar
    • Export Citation
  • 97.

    van der Kaaij MA, Heutte N, Le Stang N. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:28252832.

    • Search Google Scholar
    • Export Citation
  • 98.

    Hodgson DC, Pintilie M, Gitterman L. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007;25:1115.

    • Search Google Scholar
    • Export Citation
  • 99.

    Martin WG, Ristow KM, Habermann TM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 100.

    Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376380.

    • Search Google Scholar
    • Export Citation
  • 101.

    Evens AM, Cilley J, Ortiz T. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545552.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 1936 1386 124
PDF Downloads 547 363 43
EPUB Downloads 0 0 0